|
1
|
Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time?
|
Eur J Nucl Med Mol Imaging
|
2008
|
2.74
|
|
2
|
Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
|
Clin Nucl Med
|
2012
|
2.22
|
|
3
|
Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer.
|
Eur J Nucl Med Mol Imaging
|
2007
|
1.93
|
|
4
|
An original case of isolated unilateral adrenal metastasis from penile carcinoma: documentation by 18F-FDG-PET imaging and histopathology.
|
Hell J Nucl Med
|
2010
|
1.49
|
|
5
|
Age-related changes in the metabolic activity and distribution of the red marrow as demonstrated by 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography.
|
Mol Imaging Biol
|
2007
|
1.48
|
|
6
|
Is PET-CT the only option?
|
Eur J Nucl Med Mol Imaging
|
2007
|
1.48
|
|
7
|
The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions.
|
J Nucl Med
|
2007
|
1.47
|
|
8
|
Critical considerations on the combined use of ¹⁸F-FDG and ¹⁸F-fluoride for PET assessment of metastatic bone disease.
|
Eur J Nucl Med Mol Imaging
|
2013
|
1.44
|
|
9
|
A pilot study to assess the utility of SPECT/CT-based lymph node imaging to localize lymph nodes that drain the arm in patients undergoing treatment for breast cancer.
|
Breast Cancer Res Treat
|
2009
|
1.42
|
|
10
|
Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.
|
Mol Imaging Biol
|
2009
|
1.42
|
|
11
|
Splinting of penis following microvascular reconstruction-A simple inexpensive method.
|
Indian J Plast Surg
|
2009
|
1.39
|
|
12
|
Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders.
|
Eur J Nucl Med Mol Imaging
|
2011
|
1.27
|
|
13
|
Role of modern imaging techniques for diagnosis of infection in the era of 18F-fluorodeoxyglucose positron emission tomography.
|
Clin Microbiol Rev
|
2008
|
1.16
|
|
14
|
FDG PET/CT in carcinoma of unknown primary.
|
Eur J Nucl Med Mol Imaging
|
2009
|
1.13
|
|
15
|
FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries.
|
Eur J Nucl Med Mol Imaging
|
2007
|
1.13
|
|
16
|
A recovery coefficient method for partial volume correction of PET images.
|
Ann Nucl Med
|
2009
|
1.12
|
|
17
|
Diagnostic performance of FDG-PET, MRI, and plain film radiography (PFR) for the diagnosis of osteomyelitis in the diabetic foot.
|
Mol Imaging Biol
|
2009
|
1.11
|
|
18
|
Underestimated role of 18F-FDG PET for HCC evaluation and promise of 18F-FDG PET/MR imaging in this setting.
|
J Nucl Med
|
2013
|
1.09
|
|
19
|
A new dimension of FDG-PET interpretation: assessment of tumor biology.
|
Eur J Nucl Med Mol Imaging
|
2011
|
1.04
|
|
20
|
Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer?
|
Eur J Nucl Med Mol Imaging
|
2007
|
1.01
|
|
21
|
SUVmax of 2.5 should not be embraced as a magic threshold for separating benign from malignant lesions.
|
Eur J Nucl Med Mol Imaging
|
2013
|
0.99
|
|
22
|
Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer.
|
Mol Imaging Biol
|
2009
|
0.97
|
|
23
|
Potential of (18)F-FDG-PET as a valuable adjunct to clinical and response assessment in rheumatoid arthritis and seronegative spondyloarthropathies.
|
World J Radiol
|
2012
|
0.97
|
|
24
|
Chondroid hamartoma presenting as solitary pulmonary nodule: results of dual time point (18)F-fluorodeoxyglucose-PET and comparison with (18)F-fluorothymidine PET and histopathology.
|
Hell J Nucl Med
|
2011
|
0.96
|
|
25
|
Dual ectopic thyroid.
|
Indian Pediatr
|
2006
|
0.94
|
|
26
|
Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET.
|
Nucl Med Commun
|
2008
|
0.94
|
|
27
|
Recurrence of dermatofibrosarcoma protuberans in post-surgical scar detected by 18F-FDG-PET imaging.
|
Hell J Nucl Med
|
2009
|
0.93
|
|
28
|
Usefulness of non attenuation corrected 18F-FDG-PET images for optimal assessment of disease activity in patients with lymphoma.
|
Hell J Nucl Med
|
2009
|
0.92
|
|
29
|
The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression.
|
J Neurooncol
|
2007
|
0.91
|
|
30
|
Detection and global quantification of cardiovascular molecular calcification by fluoro18-fluoride positron emission tomography/computed tomography--a novel concept.
|
Hell J Nucl Med
|
2011
|
0.90
|
|
31
|
(18)F-FDG-PET assessment of early treatment response of articular and extra-articular foci in newly diagnosed rheumatoid arthritis.
|
Hell J Nucl Med
|
2012
|
0.90
|
|
32
|
Optimizing interventions for preventing uptake in the brown adipose tissue in FDG-PET.
|
Eur J Nucl Med Mol Imaging
|
2008
|
0.90
|
|
33
|
Adverse functional effects of chemotherapy on whole-brain metabolism: a PET/CT quantitative analysis of FDG metabolic pattern of the "chemo-brain".
|
Clin Nucl Med
|
2014
|
0.89
|
|
34
|
Potential role of FDG PET imaging in predicting metastatic potential and assessment of therapeutic response to neoadjuvant chemotherapy in Ewing sarcoma family of tumors.
|
Clin Nucl Med
|
2011
|
0.89
|
|
35
|
A pilot study of changes in (18)F-FDG uptake, calcification and global metabolic activity of the aorta with aging.
|
Hell J Nucl Med
|
2009
|
0.88
|
|
36
|
Primary paraganglioma of thyroid presenting as solitary thyroid mass.
|
J Cancer Res Ther
|
2011
|
0.87
|
|
37
|
FDG PET/CT in Crohn's disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity.
|
Eur J Nucl Med Mol Imaging
|
2013
|
0.86
|
|
38
|
Functional imaging of brown adipose tissue with PET: can this provide new insights into the pathophysiology of obesity and thereby direct antiobesity strategies?
|
Nucl Med Commun
|
2008
|
0.86
|
|
39
|
Impact of FDG-PET and -PET/CT imaging in the clinical decision-making of ovarian carcinoma: an evidence-based approach.
|
Womens Health (Lond Engl)
|
2012
|
0.86
|
|
40
|
Fluorodeoxyglucose-positron emission tomography imaging characteristics of unusual cystic metastasis on the liver surface arising from gallbladder carcinoma.
|
Jpn J Radiol
|
2009
|
0.85
|
|
41
|
PET and PET/CT for unknown primary tumors.
|
Methods Mol Biol
|
2011
|
0.84
|
|
42
|
The effects of aging on testicular volume and glucose metabolism: an investigation with ultrasonography and FDG-PET.
|
Mol Imaging Biol
|
2011
|
0.84
|
|
43
|
Bone marrow and not bone is the primary site for skeletal metastasis: critical role of [18F]fluorodeoxyglucose positron emission tomography in this setting.
|
J Clin Oncol
|
2007
|
0.83
|
|
44
|
FDG uptake in unilateral breast related to breastfeeding practice in a patient of pulmonary hydatid cyst.
|
Clin Nucl Med
|
2012
|
0.83
|
|
45
|
Beta-cell imaging: opportunities and limitations.
|
J Nucl Med
|
2011
|
0.83
|
|
46
|
Enhanced myocardial fluorodeoxyglucose uptake following Adriamycin-based therapy: Evidence of early chemotherapeutic cardiotoxicity?
|
World J Radiol
|
2012
|
0.82
|
|
47
|
Revolutionary impact of PET and PET-CT on the day-to-day practice of medicine and its great potential for improving future health care.
|
Nucl Med Rev Cent East Eur
|
2009
|
0.82
|
|
48
|
Detection by (18)F-FDG PET of unsuspected extensive bone marrow metastases in a case of basosquamous carcinoma of the cheek.
|
Hell J Nucl Med
|
2011
|
0.82
|
|
49
|
Examining recombinant human TSH primed ¹³¹I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol.
|
Eur J Nucl Med Mol Imaging
|
2014
|
0.82
|
|
50
|
Central photopenic lesions on FDG-PET scan in a patient with peripheral T cell lymphoma.
|
Ann Nucl Med
|
2008
|
0.82
|
|
51
|
Feasibility of automated partial-volume correction of SUVs in current PET/CT scanners: can manufacturers provide integrated, ready-to-use software?
|
J Nucl Med
|
2008
|
0.82
|
|
52
|
Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
|
Nucl Med Commun
|
2016
|
0.81
|
|
53
|
The effect of age, menopausal state, and breast density on (18)F-FDG uptake in normal glandular breast tissue.
|
J Nucl Med
|
2010
|
0.81
|
|
54
|
Staging with PET and the "Will Rogers" effect: redefining prognosis and survival in patients with cancer.
|
Eur J Nucl Med Mol Imaging
|
2008
|
0.81
|
|
55
|
Evaluation of diagnostic performance of 18F-FDG-PET compared to CT in detecting potential causes of fever of unknown origin in an academic centre.
|
Hell J Nucl Med
|
2011
|
0.81
|
|
56
|
Age-related structural and functional changes in the breast: multimodality correlation with digital mammography, computed tomography, magnetic resonance imaging, and positron emission tomography.
|
Semin Nucl Med
|
2007
|
0.81
|
|
57
|
Defining co-related parameters between 'metabolic' flare and 'clinical', 'biochemical', and 'osteoblastic' flare and establishing guidelines for assessing response to treatment in cancer.
|
Eur J Nucl Med Mol Imaging
|
2007
|
0.80
|
|
58
|
Quantitative assessment of the hepatic metabolic volume product in patients with diffuse hepatic steatosis and normal controls through use of FDG-PET and MR imaging: a novel concept.
|
Mol Imaging Biol
|
2009
|
0.80
|
|
59
|
FDG-PET in the clinical management of carcinoma of unknown primary with metastatic cervical lymphadenopathy: shifting gears from detecting the primary to planning therapeutic strategies.
|
Eur J Nucl Med Mol Imaging
|
2006
|
0.80
|
|
60
|
Reduced grey matter metabolism due to white matter edema allows optimal assessment of brain tumors on 18F-FDG-PET.
|
Hell J Nucl Med
|
2011
|
0.80
|
|
61
|
18F-FDG PET/CT as a sensitive and early treatment monitoring tool: will this become the major thrust for its clinical application in infectious and inflammatory disorders?
|
J Nucl Med
|
2011
|
0.80
|
|
62
|
Combined (18)F-FDG and fluoride approach in PET/CT imaging: is there a clinical future?
|
J Nucl Med
|
2009
|
0.79
|
|
63
|
Amyloid-β imaging with PET in Alzheimer's disease: is it feasible with current radiotracers and technologies?
|
Eur J Nucl Med Mol Imaging
|
2012
|
0.79
|
|
64
|
Intense FDG uptake in the spleen due to recent granulocyte-macrophage colony-stimulating factor administration: follow-up scan clarifying the situation.
|
J Cancer Res Ther
|
2011
|
0.79
|
|
65
|
Understanding and fighting cancer cachexia syndrome: can PET help?
|
Nucl Med Commun
|
2012
|
0.79
|
|
66
|
Selecting the optimal image segmentation strategy in the era of multitracer multimodality imaging: a critical step for image-guided radiation therapy.
|
Eur J Nucl Med Mol Imaging
|
2009
|
0.79
|
|
67
|
Unsuspected metastatic male breast nodule from synovial sarcoma detected by FDG PET.
|
Clin Nucl Med
|
2005
|
0.79
|
|
68
|
Suboptimal and inadequate quantification: an alarming crisis in medical applications of PET.
|
Eur J Nucl Med Mol Imaging
|
2011
|
0.78
|
|
69
|
Assessing global cardiovascular molecular calcification with 18F-fluoride PET/CT: will this become a clinical reality and a challenge to CT calcification scoring?
|
Eur J Nucl Med Mol Imaging
|
2012
|
0.78
|
|
70
|
Imaging for the diagnosis of thyroid cancer.
|
Expert Opin Med Diagn
|
2009
|
0.78
|
|
71
|
Relation between popliteal-tibial artery atherosclerosis and global glycolytic metabolism in the affected diabetic foot: a pilot study using quantitative FDG-PET.
|
J Am Podiatr Med Assoc
|
2012
|
0.78
|
|
72
|
Adding surgery as a complementary approach to radioiodine therapy in patients of differentiated thyroid carcinoma with large solitary flat bone metastases: the unresolved issues.
|
J Surg Oncol
|
2011
|
0.78
|
|
73
|
FDG PET imaging for diagnosing prosthetic joint infection: discussing the facts, rectifying the unsupported claims and call for evidence-based and scientific approach.
|
Eur J Nucl Med Mol Imaging
|
2013
|
0.78
|
|
74
|
Evolving role of FDG PET imaging in assessing joint disorders: a systematic review.
|
Eur J Nucl Med Mol Imaging
|
2011
|
0.78
|
|
75
|
Bilateral renal metastases from papillary thyroid carcinoma on post 131I treatment scan: flip-flop sign, radioiodine SPET, 18F-FDG PET, CECT and histopathological correlation.
|
Hell J Nucl Med
|
2011
|
0.78
|
|
76
|
Evolving concept of imaging bone marrow metastasis in the twenty-first century: critical role of FDG-PET.
|
Eur J Nucl Med Mol Imaging
|
2008
|
0.78
|
|
77
|
Imaging with (18)F-FDG-PET in infective endocarditis: promising role in difficult diagnosis and treatment monitoring.
|
Hell J Nucl Med
|
2009
|
0.78
|
|
78
|
FDG avid "abdominal band" representing omental cake in mucinous adenocarcinoma of the appendix: potential implications for disease monitoring with FDG-PET in this setting.
|
J Cancer Res Ther
|
2011
|
0.78
|
|
79
|
Should FDG-PET imaging be considered on a routine basis in clinical trials for carcinoma of esophagus to assure uniformity of protocols among sites?
|
Eur J Nucl Med Mol Imaging
|
2007
|
0.78
|
|
80
|
Equilibrium radionuclide angiocardiography: Its usefulness in current practice and potential future applications.
|
World J Radiol
|
2012
|
0.78
|
|
81
|
Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
|
Clin Nucl Med
|
2014
|
0.78
|
|
82
|
PET and PET/CT in gastrointestinal stromal tumours: the unanswered questions and the potential newer applications.
|
Eur J Nucl Med Mol Imaging
|
2010
|
0.77
|
|
83
|
Is it time to incorporate quantitative functional imaging data, FDG PET in particular, into the response evaluation criteria in solid tumours?
|
Nucl Med Commun
|
2006
|
0.77
|
|
84
|
Increased 18F-FDG uptake within the reticuloendothelial system in patients with active lung cancer on PET imaging may indicate activation of the systemic immune response.
|
Hell J Nucl Med
|
2010
|
0.77
|
|
85
|
Emerging role of FDG-PET for optimal response assessment in infectious diseases and disorders.
|
Expert Rev Anti Infect Ther
|
2011
|
0.77
|
|
86
|
Quantification of aging effects upon global knee inflammation by 18F-FDG-PET.
|
Nucl Med Commun
|
2016
|
0.77
|
|
87
|
Advantages of surgical extirpation in addition to radioiodine therapy in differentiated thyroid carcinoma patients with a solitary large-volume skeletal metastasis with small-volume oligometastatic disease in the rest of the whole body.
|
J Cancer Res Ther
|
2013
|
0.77
|
|
88
|
Brain 18F-FDG-PET characteristics in patients with paraneoplastic neurological syndrome and its correlation with clinical and MRI findings.
|
Nucl Med Commun
|
2014
|
0.77
|
|
89
|
Value of 18F-FDG PET negativity and Tg suppressibility as markers of prognosis in patients with elevated Tg and 131I-negative differentiated thyroid carcinoma (TENIS syndrome).
|
Nucl Med Commun
|
2015
|
0.77
|
|
90
|
Ovarian dermoid cyst serendipitously detected by pelvic radioiodine-(131)I uptake and by diffusion weighted MRI in a post-thyroidectomy case of papillary thyroid carcinoma.
|
Hell J Nucl Med
|
2013
|
0.76
|
|
91
|
The feasibility of low-dose oral lithium therapy and its effect on thyroidal radioiodine uptake, retention, and hormonal parameters in various subcategories of hyperthyroid patients: a pilot study.
|
Nucl Med Commun
|
2016
|
0.76
|
|
92
|
Impact of fluorodeoxyglucose PET on the management of esophageal cancer.
|
Nucl Med Commun
|
2009
|
0.76
|
|
93
|
Quantitative assessment of global lung inflammation following radiation therapy using FDG PET/CT: a pilot study.
|
Eur J Nucl Med Mol Imaging
|
2013
|
0.76
|
|
94
|
Tumor metabolism measured by partial volume corrected standardized uptake value varies considerably in primary and metastatic sites in patients with lung cancer. A new observation.
|
Hell J Nucl Med
|
2009
|
0.76
|
|
95
|
Dose fractionation in 131I-metaiodobenzylguanidine (MIBG) therapy: should the tumour biology and intent of therapy be the guide?
|
Eur J Nucl Med Mol Imaging
|
2010
|
0.76
|
|
96
|
Early FDG-PET response-adapted risk stratification and further therapeutic decision-making in lymphoma: will this replace the established prognostic indices and be the standard-of-care in clinical management?
|
Eur J Nucl Med Mol Imaging
|
2009
|
0.75
|
|
97
|
Imaging the infected heart.
|
Sci Transl Med
|
2011
|
0.75
|
|
98
|
Characterization of hilar and mediastinal foci on 18F-FDG PET: new variables.
|
J Nucl Med
|
2009
|
0.75
|
|
99
|
Multifaceted role of lymphatic mapping by SPECT/CT hybrid imaging in the multimodality management of patients with cancer.
|
Eur J Nucl Med Mol Imaging
|
2009
|
0.75
|
|
100
|
Doughnut sign on FDG-PET scan in a ruptured lung hydatid cyst.
|
Indian J Chest Dis Allied Sci
|
2012
|
0.75
|
|
101
|
Nuclear medicine, scientific publishing and the era of cost containment: what factors hold the key?
|
Eur J Nucl Med Mol Imaging
|
2012
|
0.75
|
|
102
|
Quantitative analysis of SPECT imaging parameters in patients with resting perfusion defects on myocardial perfusion scintigraphy.
|
Indian J Nucl Med
|
2010
|
0.75
|
|
103
|
Potential role of FDG PET/CT imaging for assessing venous thromboembolic disorders.
|
Clin Nucl Med
|
2012
|
0.75
|
|
104
|
Should the nuclear medicine community continue to underestimate the potential of 18F-FDG-PET/CT with present generation scanners for the diagnosis of prosthetic joint infection?
|
Nucl Med Commun
|
2015
|
0.75
|
|
105
|
Increased 18F-FDG uptake suggests synovial inflammatory reaction with osteoarthritis: preliminary in-vivo results in humans.
|
Nucl Med Commun
|
2015
|
0.75
|
|
106
|
Dual malignancies in the setting of differentiated thyroid carcinoma: their synchronous or metachronous nature, impact of radioiodine treatment on occurrence of second malignancy and other associated variables.
|
Nucl Med Commun
|
2014
|
0.75
|
|
107
|
Feasibility and performance of an adaptive contrast-oriented FDG PET/CT quantification technique for global disease assessment of malignant pleural mesothelioma and a brief review of the literature.
|
Hell J Nucl Med
|
2015
|
0.75
|
|
108
|
Atherosclerotic inflammatory activity in the aorta and its correlation with aging and gender as assessed by 18F-FDG-PET.
|
Hell J Nucl Med
|
2013
|
0.75
|
|
109
|
Solitary anterior abdominal wall metastasis from osteogenic sarcoma of fibula as detected by FDG-PET imaging.
|
J Cancer Res Ther
|
2011
|
0.75
|
|
110
|
[¹³¹I]Metaiodobenzylguanidine therapy in neural crest tumors: varying outcome in different histopathologies.
|
Nucl Med Commun
|
2011
|
0.75
|
|
111
|
A nonpalpable toxic thyroid lobe besides a malignant lobe.
|
Hell J Nucl Med
|
2009
|
0.75
|
|
112
|
Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
|
Clin Nucl Med
|
2017
|
0.75
|
|
113
|
PET tracer for evaluating brain tumors: a clinical need-based rational approach.
|
Nucl Med Commun
|
2010
|
0.75
|
|
114
|
Extensive 99mTc-MDP uptake in metastasis to contralateral pleura from osteosarcoma of femur: an indirect measure of extent of disease involvement at diagnosis.
|
J Cancer Res Ther
|
2013
|
0.75
|
|
115
|
Age-related inflammatory changes in the spine as demonstrated by (18)F-FDG-PET:observation and insight into degenerative spinal changes.
|
Hell J Nucl Med
|
2012
|
0.75
|
|
116
|
Primary malignant melanoma presenting as FDG avid large necrotic splenic mass with metastatic retroperitoneal adenopathy: FDG-PET and histopathological correlation.
|
J Cancer Res Ther
|
2011
|
0.75
|
|
117
|
Striking asymmetry in cerebral metabolism in Dyke-Davidoff-Masson (DDM) syndrome: FDG-PET and MRI correlation.
|
Acta Neurochir (Wien)
|
2013
|
0.75
|
|
118
|
Bilateral symmetrical adrenal hypermetabolism on FDG PET in paraneoplastic Cushing syndrome in breast carcinoma: correlation with contrast-enhanced computed tomography.
|
Clin Nucl Med
|
2010
|
0.75
|
|
119
|
Developing a unified imaging approach for neuroendocrine tumours with the evolution of PET-CT with ⁶⁸Ga-labelled somatostatin analogues: could this be tailored according to specific clinical context and individual patient requirement?
|
Nucl Med Commun
|
2012
|
0.75
|
|
120
|
Increased muscle 18F-FDG uptake in an agitated child.
|
Hell J Nucl Med
|
2011
|
0.75
|
|
121
|
(18)F-FDG-PET in restaging primary maxillary sinus melanoma with isolated gall bladder metastasis.
|
Hell J Nucl Med
|
2009
|
0.75
|
|
122
|
18F-FDG uptake in small bowel intussusception in a patient of Langerhans cell histiocytosis and its resolution following successful conservative medical management.
|
Hell J Nucl Med
|
2011
|
0.75
|
|
123
|
Thyroid Incidentaloma on 68Ga-PSMA-11 PET/CT Leading to Detection of Thyroid Metastasis in Metastatic Prostate Carcinoma.
|
Clin Nucl Med
|
2022
|
0.75
|
|
124
|
Examining a hypothetical quantitative model for better approximation of culprit coronary artery and site of stenosis on 99mTc-sestamibi gated myocardial perfusion SPECT.
|
Nucl Med Commun
|
2016
|
0.75
|
|
125
|
Relevance of a thyroid phantom in estimating thyroid radioiodine uptake values using a gamma camera.
|
Nucl Med Commun
|
2015
|
0.75
|
|
126
|
Cardiac involvement from adenocarcinoma of the lung at diagnosis detected by (18)F-FDG-PET imaging.
|
Hell J Nucl Med
|
2008
|
0.75
|
|
127
|
Estimation of sacroiliac joint index in normal subjects of various age groups: comparative evaluation of four different methods of quantification in skeletal scintigraphy.
|
Nucl Med Rev Cent East Eur
|
2013
|
0.75
|
|
128
|
Response to low-dose oral capecitabine monotherapy in an elderly frail patient with metastatic breast carcinoma and impaired renal function: documentation by fluorodeoxyglucose positron emission tomography.
|
Jpn J Radiol
|
2011
|
0.75
|
|
129
|
FDG-avid thyroid incidentaloma in advanced gastrointestinal stromal tumor: metachronous dual primaries.
|
Indian J Gastroenterol
|
2007
|
0.75
|
|
130
|
How a tertiary medical nuclear medicine department at the Himalayan area in India can be established and function in an exemplary manner. Basic rules revisited.
|
Hell J Nucl Med
|
2015
|
0.75
|
|
131
|
Functional oncoimaging techniques with potential clinical applications.
|
Front Biosci (Elite Ed)
|
2012
|
0.75
|
|
132
|
Aggressive poorly differentiated adenocarcinoma of the lung diagnosed 13 months after initial diagnosis of papillary thyroid carcinoma with "non-iodine concentrating" pulmonary metastasis.
|
Hell J Nucl Med
|
2012
|
0.75
|
|
133
|
Partial volume correction and image segmentation for accurate measurement of standardized uptake value of grey matter in the brain.
|
Nucl Med Commun
|
2015
|
0.75
|
|
134
|
Second primary malignancy of breast in a patient of gastrointestinal stromal tumor presenting as fluoro-deoxyglucose-avid breast incidentaloma in fluoro-deoxyglucose-positron emission tomography.
|
J Cancer Res Ther
|
2011
|
0.75
|
|
135
|
Role of SPECT/CT, versus traditional practices, in individualizing treatment of thyroid carcinoma.
|
J Nucl Med
|
2012
|
0.75
|
|
136
|
Defining the role of modern imaging techniques in assessing lymph nodes for metastasis in cancer: evolving contribution of PET in this setting.
|
Eur J Nucl Med Mol Imaging
|
2011
|
0.75
|
|
137
|
Displaced left kidney masquerading as splenic blush in 99mTc-DTPA GFR study in a patient of paravertebral primitive neuroectodermal tumor.
|
J Cancer Res Ther
|
2011
|
0.75
|
|
138
|
Effects of age and cardiovascular risk factors on (18)F-FDG PET/CT quantification of atherosclerosis in the aorta and peripheral arteries.
|
Hell J Nucl Med
|
2015
|
0.75
|
|
139
|
Furosemide for the diagnosis of complete or partial ureteropelvic junction obstruction.
|
Hell J Nucl Med
|
2010
|
0.75
|
|
140
|
Personalized treatment approach to gastroenteropancreatic neuroendocrine tumors: a medical oncologist's perspective.
|
Eur J Gastroenterol Hepatol
|
2016
|
0.75
|
|
141
|
Evaluation of the (14)C-urea breath test using indigenously produced (14)C-urea capsules and a modified technique for trapping exhaled breath: a pilot study.
|
Nucl Med Commun
|
2014
|
0.75
|
|
142
|
Benefit of treating patients of subclinical hypothyroidism with subfertility: anecdotal observation or true association?
|
Am J Med
|
2012
|
0.75
|
|
143
|
Utility of 18F-FDG-PET/CT imaging in the diagnosis of appendicitis.
|
Hell J Nucl Med
|
2009
|
0.75
|
|
144
|
Selected cases demonstrating the value of furosemide-primed 18F-FDG PET in identifying adrenal involvement.
|
J Nucl Med Technol
|
2005
|
0.75
|
|
145
|
Functional mapping of pattern and probability of locoregional and distant metastases: can FDG-PET/CT imaging data be the basis for multidimensional scaling in patients with cancer?
|
Eur J Nucl Med Mol Imaging
|
2008
|
0.75
|
|
146
|
Breast recurrence of primary rectal lymphoma: documentation by (18)F-FDG-PET and histopathology.
|
Hell J Nucl Med
|
2012
|
0.75
|